Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHYOX8 pediatric nedosiran study in primary hyperoxaluria
jRCT2041220026Phase 2Completed
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Sep 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of nedosiran in Primary hyperoxaluria (PH), sponsored by Dicerna Pharmaceuticals, Inc. Primary endpoints: Percent change from baseline to Month 6 in spot urinary oxalate-to-creatinine ratio and Absolute change from baseline to Month 6 in spot urinary oxalate-to-creatinine ratio. Started Sep 2022; status: completed.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)
Beyond the preview
Go deeper on jRCT2041220026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220026.